Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of an assay website that allows droplet digital PCR (ddPCR™) users to locate existing assays or design new ones for mutation ...
Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading Korean developer of ...
"The real-time PCR using plasma or body fluids could be a suitable first test for the detection of EGFR mutations." –Lee et al., Asia-Pacific Journal of Clinical Oncology, 2022 To this end, Kyunghoon ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...
Quantification of empty and full adeno-associated virus (AAV) capsids is crucial for maximizing viral vectors used in gene therapy. The launch of the Vericheck ddPCR Empty-Full Capsid Kit expands this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results